Sethi Sidharth K, Sinha Rajiv, Jha Pranaw, Wadhwani Nikita, Raghunathan Veena, Dhaliwal Maninder, Bansal Shyam B, Kher Vijay, Lobo Valentine, Sharma Jyoti, Raina Rupesh
Kidney Institute, Medanta, The Medicity, Gurgaon, Haryana 122001, India.
Institute of Child Health and AMRI Hospital, Kolkata, West Bengal, India.
Hemodial Int. 2018 Apr;22(2):228-234. doi: 10.1111/hdi.12605. Epub 2017 Oct 3.
Sustained low-efficiency dialysis (SLED) has emerged as a cost effective alternative to Continuous Renal Replacement Therapy in the management of hemodynamically unstable adult patients with acute kidney injury. The objective of the study was to document the SLED practices in these centers, and to look at the feasibility, and tolerability of SLED in critically sick pediatric patients.
It was a retrospective record review from January 2010 to June 2016 done in four tertiary pediatric nephrology centers in India. All pediatric patients undergoing SLED in the collaborating centers were included in the study. Basic demographic data, prescription parameters and outcomes of patients were recorded.
During the study period a total of 68 children received 211 sessions of SLED. PRISM score at admission in patients was 13.33 ± 9.15. Fifty-seven patients were ventilated (84%). Most of the patients had one or more organ system involved in addition to renal (n = 64; 94%). Heparin free sessions were achievable in 153 sessions (72%). Out of 211 sessions, 148 sessions were on at least one inotrope (70.1%). Overall premature terminations had to be done in 27 sessions (13% of all sessions), out of which 7 sessions had to be terminated due to circuit clotting (3.3%). Intradialytic hypotension or need for inotrope escalation was seen in 31 (15%) sessions but termination of the session for drop in BP was required in only 20 (9%) sessions.
SLED is a feasible method of providing renal replacement in critically ill pediatric patients.
持续性低效透析(SLED)已成为治疗血流动力学不稳定的急性肾损伤成年患者时,一种具有成本效益的连续性肾脏替代治疗替代方案。本研究的目的是记录这些中心的SLED实践情况,并探讨SLED在危重症儿科患者中的可行性和耐受性。
这是一项于2010年1月至2016年6月在印度四个三级儿科肾脏病中心进行的回顾性记录审查。协作中心所有接受SLED治疗的儿科患者均纳入研究。记录患者的基本人口统计学数据、处方参数和治疗结果。
在研究期间,共有68名儿童接受了211次SLED治疗。患者入院时的PRISM评分为13.33±9.15。57名患者接受了通气治疗(84%)。大多数患者除肾脏外还涉及一个或多个器官系统(n = 64;94%)。153次治疗(72%)可实现无肝素治疗。在211次治疗中,148次治疗至少使用了一种血管活性药物(70.1%)。总体而言,27次治疗(占所有治疗的13%)不得不提前终止,其中7次治疗因体外循环凝血而终止(3.3%)。31次治疗(15%)出现透析中低血压或需要增加血管活性药物剂量,但仅20次治疗(9%)因血压下降而终止治疗。
SLED是为危重症儿科患者提供肾脏替代治疗的一种可行方法。